Eli Lilly and Innovent Biologics have expanded their collaboration deal and defined the distribution rights for up to three co-developed, experimental cancer drugs.

Sections:  world   
Topics:  asia   
RELATED ARTICLES
BING NEWS:
  • Eli Lilly and Company (LLY)
    After an eventful week compounded by Nvidia's (NVDA) fiscal first-quarter earnings, the major market averages (^DJI, ^IXIC, ^GSPC) are hoping to end the week on a high note and claw back some ...
    05/24/2024 - 5:00 am | View Link
  • Eli Lilly to inject $5.3bn to expand weight loss drugs factory in US
    Investment aims to boost output of Lilly's weight loss drug Zepbound and blockbuster diabetes medication Mounjaro ...
    05/24/2024 - 4:47 am | View Link
  • Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, Mounjaro
    Eli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its popular weight-loss and diabetes treatments, Zepbound and Mounjaro. The ...
    05/24/2024 - 3:29 am | View Link
  • Eli Lilly and Co
    We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
    05/23/2024 - 1:01 pm | View Link
  • Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide
    Eli Lilly And Company (NYSE:LLY) announced that Chinese regulators have approved its diabetes drug tirzepatide. This approval sets the stage for heightened competition with Novo Nordisk A/S (NYSE:NVO) ...
    05/21/2024 - 2:36 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More News